20201-55-2

Usage

Uses

Used in Pharmaceutical Industry:
(S)-4-Amino-6-bromo-7-((3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-7,7a-dihydro-4aH-pyrrolo[2,3-d]pyrimidine-5-carbonitrile is used as a potential pharmaceutical compound for its possible biological activity. The presence of various functional groups and its complex structure suggest that it may interact with biological targets, making it a candidate for further research and development in the pharmaceutical field.
Used in Chemical Research:
In the field of chemical research, (S)-4-Amino-6-bromo-7-((3R,4S,5R)-3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-7,7a-dihydro-4aH-pyrrolo[2,3-d]pyrimidine-5-carbonitrile can be used as a starting material or a structural motif for the synthesis of new compounds with potential applications in various industries, including pharmaceuticals, materials science, and agrochemistry.

InChI:InChI=1/C12H12BrN5O4/c13-9-4(1-14)6-10(15)16-3-17-11(6)18(9)12-8(21)7(20)5(2-19)22-12/h3,5,7-8,12,19-21H,2H2,(H2,15,16,17)/t5-,7-,8-,12-/m1/s1

Upstream product

• 151707-53-8 (2R,3R,4R,5R)-2-(4-amino-6-bromo-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((benzoyloxy)methyl)tetrahydrofuran-3,4-diyl dibenzoate 
• 606-58-6 Vengicide 

Downstream Products

• 606-58-6 Vengicide 

Relevant academic research and scientific papers

Synthesis of 8-(1,2,3-triazol-1-yl)-7-deazapurine nucleosides by azide–alkyne click reactions and direct C[sbnd]H bond functionalization

Treatment of toyocamycin or sangivamycin with 1,3-dibromo-5,5-dimethylhydantoin in MeOH (rt/30?min) gave 8-bromotoyocamycin and 8-bromosangivamycin in good yields. Nucleophilic aromatic substitution of 8-bromotoyocamycin with sodium azide provided novel 8

New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms

A number of new nucleoside derivatives are disclosed as inhibitors of DOT1L activity. SARs established that DOT1L inhibition could be achieved through incorporation of polar groups and small heterocycles at the 5-position (5, 6, 12) or by the application of alternative nitrogenous bases (18). Based on these results, CN-SAH (19) was identified as a potent and selective inhibitor of DOT1L activity where the polar 5-nitrile group was shown by crystallography to bind in the hydrophobic pocket of DOT1L. In addition, we show that a polar nitrile group can be used as a non-traditional replacement for heavy halogen atoms.

Studies on the glycosylation of pyrrolo[2,3-d] pyrimidines with 1-O-acetyl-2,3,5-tri-O-benzoyl -β-D-ribofuranose: The formation of regioisomers during toyocamycin and 7-deazainosine syntheses

Glycosylation of silylated 4-amino-6-bromo-5-cyano-7H-pyrrolo[2,3-d] pyrimidine (9) with 1-O-acetyl-2,3,5-tri-O-benzoyl - d-ribofuranose (10) under "one-pot" glycosylation conditions (MeCN, TMSOTf) yielded the N-7 isomer 11 together with the N-1 compound 13 (ratio = 2:1). When the same conditions were applied to 4-hydroxy-7H-pyrrolo[2,3-d]pyrimidine (21) the N-3 isomer 22 was the only glycosylation product formed in almost quantitative yield.